Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5707324 | 0.98 | CASP2 (0.45) | CASP2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14842883 | 0.87 | FAAH (0.50) | CASP2CNR1CNR2HPGDFAAH | |
| SCHEMBL20606606 | 0.85 | LMNA (0.40) | CASP2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL15247218 | 0.85 | FAAH (0.59) | CNR1CNR2FAAH | |
| SCHEMBL20883259 | 0.84 | FAAH (0.62) | CNR1CNR2FAAH | |
| SCHEMBL14877628 | 0.81 | HDAC3 (0.50) | CASP2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL841327 | 0.81 | MEN1 (0.48) | LMNAPOLBHPGDALDH1A1KDM4E | |
| SCHEMBL2035994 | 0.81 | KDM4E (0.39) | LMNAPOLBCNR1CNR2HPGD | |
| SCHEMBL30181819 | 0.80 | CNR1 (0.39) | LMNAPOLBCNR1CNR2HPGD | |
| SCHEMBL13407576 | 0.80 | CNR1 (0.39) | LMNAPOLBCNR1CNR2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366829-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20230165253-A1 | CROP ENHANCEMENT | SYNGENTA CROP PROTECTION AG (CH) | 2023-06-01 | — | — | US | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| CN-106432311-A | Processes and intermediates for producing azaindoles | 沃泰克斯药物股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106336413-A | Compounds used as JAK inhibitor, and use of compounds | 广东东阳光药业有限公司 | 2017-01-18 | — | — | CN | disclosed |
| US-9266882-B2 | Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications | MEI PHARMA, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HELSINN HEALTHCARE SA (CH) | 2015-02-05 | — | — | US | disclosed |
| US-8889710-B2 | Parasiticidal dihydroisoxazole compounds | ELI LILLY AND COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2785381-A1 | FLUORINE-18 AND CARBON-11 LABELED RADIOLIGANDS FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING FOR LRRK2 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | PANACEA BIOTEC PHARMA LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-7754746-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-07-13 | — | — | US | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-09-17 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | NOVARTIS AG | 2008-12-25 | — | — | US | disclosed |
| WO-2007084557-A2 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007068473-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234132-A1 | 5-PHENYL-THIAZOL-2-YL-UREA DERIVATIVES AND USE AS PI3 KINASE INHIBITORS | CNKSR1, CDK8, MAPK8 | CASP2 2109/4885HDAC3 238/4885HDAC1 505/4885 |
| US-20230165253-A1 | CROP ENHANCEMENT | CBR3, POF1B, MYB | CASP2 3109/4885HDAC3 862/4885HDAC1 2349/4885 |
| US-20170283424-A1 | PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | CASP2 1707/4885HDAC3 1881/4885HDAC1 1487/4885 |
| US-20100311732-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DPP4, DPP3, DPP8 | CASP2 1648/4885HDAC3 119/4885HDAC1 615/4885 |
| US-20080319033-A1 | 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma | AKT3, PIK3R3, PIK3CD | CASP2 3029/4885HDAC3 404/4885HDAC1 548/4885 |
| US-20150038703-A1 | IMIDAZO[1,2-a]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | HDAC1, HDAC2, HDAC5 | CASP2 1740/4885HDAC3 5/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.